MiNK Therapeutics, Inc. (6Q40)

Market Open

11 Jun, 20:00

XFRA

€

8. 90

-0.3

-3.2609%

- Market Cap

- P/E Ratio

- Div Yield

38 Volume

-0.56 Eps

€ 9.2

Previous Close

Add Transaction

Day Range

8.9 9.4

Year Range

6.6 39

Want to track 6Q40 and more in your Portfolio? 🎯

Get Started For Free

Summary

6Q40 trading today lower at €8.9, a decrease of -3.2609% from yesterday's close, completing a monthly increase of 1.1364% or €0.1. Over the past 12 months, 6Q40 stock gained 5.3254%.

6Q40 is not paying dividends to its shareholders.

The last earnings report, released on May 13, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.2267%, based on the last three reports.

MiNK Therapeutics, Inc. has completed 1 stock splits, with the recent split occurring on Jan 28, 2025.

The company's stock is traded on 3 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).

6Q40 Chart

MiNK Therapeutics, Inc. (INKT) Q1 2026 Earnings Call Transcript

Seekingalpha | 3 weeks ago

MiNK Therapeutics Q1 Earnings Call Highlights

MiNK Therapeutics NASDAQ: INKT said it is advancing its off-the-shelf invariant natural killer T cell therapy platform into a randomized clinical program for severe acute lung injury and acute respiratory distress syndrome, while also reporting first-quarter 2026 financial results that management said support at least 12 months of operating runway.

Marketbeat | 4 weeks ago

MiNK Therapeutics, Inc. (INKT) Q4 2025 Earnings Call Transcript

Seekingalpha | 2 months ago

MiNK Therapeutics, Inc. (6Q40) FAQ

What is the stock price today?

The current price is €8.90.

On which exchange is it traded?

MiNK Therapeutics, Inc. is listed on XFRA.

What is its stock symbol?

The ticker symbol is 6Q40.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has MiNK Therapeutics, Inc. ever had a stock split?

MiNK Therapeutics, Inc. had 1 splits and the recent split was on Jan 28, 2025.

MiNK Therapeutics, Inc. Profile

Biotechnology Industry	Healthcare Sector	Jennifer S. Buell CEO	XFRA Exchange	US6036932019 ISIN
US Country	23 Employees	- Last Dividend	28 Jan 2025 Last Split	15 Oct 2021 IPO Date

Overview

MiNK Therapeutics, Inc. is a pioneering biopharmaceutical firm focused on the forefront of cancer and immune-mediated disease treatment. Operating from its base in New York, New York, MiNK Therapeutics leverages its expertise in the field of invariant natural killer T (iNKT) cell therapies. As a clinical-stage enterprise, its dedication lies in advancing these innovative therapies from discovery through to commercialization. Initially known as AgenTus Therapeutics, Inc., the company underwent a rebranding to better align with its focused approach towards iNKT cell therapies. Since its establishment in 2017, MiNK Therapeutics has been an integral part of the Agenus Inc. family, benefiting from the parent company's vast resources and expertise in the biopharmaceutical sector.

Products and Services

AGENT-797

At the core of MiNK Therapeutics’ product line is AGENT-797, a groundbreaking allogeneic iNKT cell therapy. This off-the-shelf therapeutic candidate stands out for its application in treating a plethora of myeloma diseases and solid tumors. Currently in Phase 1 clinical trials, AGENT-797 exemplifies MiNK Therapeutics’ commitment to unleashing the potential of iNKT cell therapies across various disease spectrums. Its development underscores the company's aim at delivering novel, effective treatments that can transform the therapeutic landscape for cancer and other immune-mediated diseases.

Contact Information

Address: 149 Fifth Avenue

Phone: 212 994 8250

Website: https://minktherapeutics.com

Blog Affiliate Program About Terms Privacy Help Contact Us